Free tool
FAERS Monitor: Silenor
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022036 or its brand name (Silenor, Doxepin Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
2,564
Serious
1,560
61% of reports
Hospitalization
637
Death reported
369
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective278
- pain228
- insomnia203
- fatigue192
- completed suicide189
- dizziness186
- fall183
- toxicity to various agents168
- anxiety167
- headache153
- off label use145
- pruritus135
- product use in unapproved indication131
- memory impairment117
- nausea117
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 20 |
| 2005 | 36 |
| 2006 | 43 |
| 2007 | 15 |
| 2008 | 13 |
| 2009 | 24 |
| 2010 | 26 |
| 2011 | 25 |
| 2012 | 46 |
| 2013 | 52 |
| 2014 | 19 |
| 2015 | 55 |
| 2016 | 146 |
| 2017 | 152 |
| 2018 | 126 |
| 2019 | 223 |
| 2020 | 191 |
| 2021 | 194 |
| 2022 | 156 |
| 2023 | 169 |
| 2024 | 261 |
| 2025 | 335 |
| 2026 | 237 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,595 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| completed suicideSignal | 189 | 18.6 | 16.3 | 3,144 |
| toxicity to various agentsSignal | 168 | 8.2 | 7.1 | 1,059 |
| memory impairmentSignal | 117 | 7.0 | 5.9 | 598 |
| insomniaSignal | 203 | 6.3 | 5.5 | 902 |
| anxietySignal | 167 | 4.8 | 4.2 | 508 |
| fallSignal | 183 | 4.5 | 3.9 | 505 |
| product use in unapproved indicationSignal | 131 | 4.3 | 3.7 | 337 |
| dizzinessSignal | 186 | 3.1 | 2.7 | 262 |
| painSignal | 228 | 3.0 | 2.7 | 320 |
| pruritusSignal | 135 | 2.9 | 2.4 | 167 |
| fatigueSignal | 192 | 2.0 | 1.8 | 102 |
| headacheSignal | 153 | 2.0 | 1.7 | 78 |
| drug ineffective | 278 | 1.7 | 1.5 | 91 |
| off label use | 145 | 1.4 | 1.2 | 14 |
| nausea | 117 | 1.2 | 1.0 | 4 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.